Emcure Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zf5u77overr6nzmbzqcfehhr.pdf

Key Takeaways


Domestic Business: The Zuventus Overhang

Satish Mehta: "We'll be back on track. And again, the other thing that I would like to say is that as Zuventus is concerned over a period of time, we have built some very strong brands. So that should also take us through."

International Markets: The Growth Engine


Portfolio & Pipeline: Biologics, Licenses and NASH

Satish Mehta: "As far we are concerned, we'll talk about the merit of the product, which is rDNA product, not synthetic, backed up by a lot of clinical data. So we'll be differentiating ourselves on the back of science, we'll be talking to the doctor."

Margins & Costs: Expansion with Eyes on Input Prices

Satish Mehta: "This is an industry-wide problem, not necessarily restricted to one company. And the advantage that we will have is that we are not in a purely generic-generic market because we have differentiated products."

Capital Allocation & Strategy


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthLow to mid-teen growthFY27
EBITDA margin expansion75 to 100 bps expansion, assuming stable regulations and macro conditionsFY27
Gross marginRemain around 60%FY27
Domestic growthGrow faster than industry (industry expected at 8-9%); low double-digitsFY27
Europe growthMid-teens CAGROver next 2 years
Bevacizumab launchLaunch in IndiaH1 FY27, pending approval
Lenacapavir registrationSeek product registrationFY27
Amphotericin B expansionExpand to Europe and rest of world; significant contribution expectedFY27
Capex₹400-425 croresFY27
Employee expensesAround 10% of revenueFY27

Key Metrics

MetricQ4 FY26
Revenue from operations₹2,470 cr, up 16.7% YoY
Domestic revenue₹977 cr, up 5.2% YoY; softness due to Zuventus restructuring
International revenue₹1,493 cr, up 25.7% YoY
Gross margin59.4%, up 160 bps YoY from 57.8%
EBITDA (excl other income)₹485 cr, up 24.5% YoY
EBITDA margin19.7%, up from 18.4% in Q4 FY25 and 19.5% in Q3 FY26
Adjusted PAT₹279 cr, up 36% YoY; adjusted PAT margin 11.3%, up 160 bps
Reported PAT₹244 cr, PAT margin 9.9%
Net debt₹1,054 cr as of March 31, 2026
FY27 revenue growth guidanceLow to mid-teen growth, assuming USD:INR at 92
FY27 EBITDA margin expansion guidance75 to 100 bps expansion, assuming stable regulations and macro conditions
Domestic business growth ex-Zuventus (Q4)Less than 8%
Field force strengthClose to 4,000 medical representatives
Field productivity₹7 lakhs per MR, up from ₹5.4 lakhs two years ago
R&D spend (FY26)₹383.5 cr, 4.2% of revenue, up 50 bps YoY